Bids are Invited For CD3 (Early T Cell Marker) Rabbit Monoclonal Antibody,CD61 (ZM33) Monospecific Mouse Monoclonal Anti in SOUTH DELHI, DELHI

The eligibility requirements include being a registered entity with the necessary operational licenses. Bidders must have proven experience supplying similar biological products to the healthcare sector and demonstrate compliance with current Good Manufacturing Practices (cGMP). It’s essential for bidders to also be able to provide documentation verifying their qualifications and relevant experience.

Bidders must adhere to stringent technical specifications that include providing documentation on the purity and efficacy of the CD3, CD61, and CD5 antibodies. Compliance with industry quality standards, along with certificates of analysis confirming the manufacturing processes and testing results, are critical. This ensures that the antibodies will perform effectively in intended applications.

Bidders must submit a comprehensive financial proposal that includes an itemized breakdown of costs. This should detail pricing for the antibodies, potential bulk purchase discounts, and payment terms. Additionally, bidders must comply with any fiscal regulations set by the Department of Health and Family Welfare to ensure their financial proposals are competitive and acceptable.

All required documents should be submitted electronically via the designated online platform specified in the tender announcement. Bidders must ensure that all necessary documentation is included during the submission to avoid disqualification. A checklist is often useful to confirm that all documents are properly prepared and submitted by the deadline.

Yes, there are specific provisions in place for Micro, Small, and Medium Enterprises (MSEs) that may include reduced financial requirements or additional support during the bidding process. These benefits aim to encourage wider participation from smaller entities in order to stimulate innovation and competition in the supply of health-related products.